Clinical Trial

TLN-372 in Advanced KRAS Mutant Solid Tumors

Name: TLN-372 in Advanced KRAS Mutant Solid Tumors — clinical trial record (NCT07204340)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors

Protocol Amendment History 1 change

notable Enrollment increased: 240 -> 270 participants 2026-07-29

Trial Details

NCT Number	NCT07204340
Lead Sponsor	Treeline Biosciences, Inc.
Conditions	KRAS Mutant Solid Tumors
Enrollment	270 participants
Start Date	2025-09-29
Primary Completion	2031-12-03 (estimated)
Study Completion	2032-04-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-28